Friday, 21 June 2024

Top 20: CHINA - Growth Despite Crackdowns

04 July 2014 | Analysis | By BioSpectrum Bureau


China has cracked down on high prices and corruption in the healthcare sector. Nonetheless, the revenue growth of publicly listed companies grew by nearly 22 percent.

Today, China accounts for nearly 50 percent share of the total market.

China's leading company Sinopharm alone is the size of combined revenue of India's publicly listed bioscience companies.

The top three companies contributed almost 62 percent share of the total revenue of China bioscience market.

China has almost eight companies which have over $1 billion in revenue.


China takes firm steps against drug makers who were caught bribing doctors and other health authorities to the extent of blacklisting them in the country.

China confiscated $362 million worth of drugs and raw materials in an action against drug counterfeiters selling over the Internet.

China is set to build its first national biobank developed in partnership by with BGI-Shenzhen and China National Genebank.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account